What this means
A small trial plans to test if capsules are safe for 20 people aged 60 to 75 with frailty. It has not started, so no results exist yet, and it cannot show whether the capsules work.
Plain-English summary written by an AI model from the registry listing.
- Status
- Opening soon
- Who can join
- Ages 60–75 · 20 people aged 60 to 75 with frailty (planned, not started)
- Where
- Not listed
The science
- Registered title
- Safety and Preliminary Efficacy of Adipose-Derived Stem Cell Secretome in Frailty (VinVital)
- Trial ID
- NCT07856602 ↗
- Phase
- PHASE 1
- Study type
- interventional
- Conditions
- Frailty Syndrome, Aging
- What is tested
- VinVital
- Sponsor
- Vinmec Research Institute of Stem Cell and Gene Technology
- Ages
- 60 Years to 75 Years
- Dates
- First posted Oct 2, 2026 · updated Oct 2, 2026
Registry summary
This is a Phase I, open-label, non-randomized clinical trial to evaluate the safety and preliminary efficacy of adipose-derived mesenchymal stem cell secretome capsules (VinVital) in patients with frailty syndrome. A total of 20 participants aged 60 to 75 will receive oral VinVital for 3 months, with an additional 3-month follow-up period (total 6 months). The primary objective is to assess safety based on the frequency and severity of adverse events (AEs) and serious adverse events (SAEs) according to CTCAE v5.0.